Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 4/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.38 |
| ▸ | PRKACA | P17612 | 2/20 | 0.38 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16152421 | 0.94 | ALB (0.48) | ALBSIRT5ROCK2PRKACAAKT3 | |
| SCHEMBL8255244 | 0.92 | ALB (0.57) | ALBSIRT5ROCK2PRKACAAKT3 | |
| SCHEMBL13783673 | 0.89 | ALB (0.43) | ALBSIRT5PTGS1PTGS2SIRT2 | |
| SCHEMBL14423080 | 0.88 | ALB (0.40) | ALBSIRT5ROCK2PRKACAAKT3 | |
| SCHEMBL10054209 | 0.88 | ALB (0.40) | ALBSIRT5ROCK2PRKACAAKT3 | |
| SCHEMBL16152399 | 0.88 | ROCK2 (0.48) | ALBSIRT5ROCK2PRKACAAKT3 | |
| SCHEMBL9363327 | 0.87 | HPGDS (0.43) | ROCK2PRKACAAKT3TLR2NPFFR1 | |
| SCHEMBL14140003 | 0.87 | ALB (0.42) | ALBSIRT5PTGS1PTGS2SIRT2 | |
| SCHEMBL12893039 | 0.86 | TLR2 (0.45) | ALBSIRT5ROCK2PRKACAAKT3 | |
| SCHEMBL16152405 | 0.86 | ROCK2 (0.51) | ALBROCK2PRKACAAKT3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281795-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281795-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | ALB 1990/4885SIRT5 4473/4885ROCK2 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.